|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,139.50 JPY | +0.94% |
|
-0.35% | +2.22% |
| 06-30 | Trump's push for the world's lowest drug prices hits snag with mid-sized companies | RE |
| 06-26 | Lupin Receives U.S. FDA Tentative Approval for Enzalutamide Tablets | MT |
| Market Cap | 3,797B 23.38B 20.53B 18.89B 17.61B 33.2B 2,223B 33.88B 227B 88.05B 1,091B 87.78B 85.88B | P/E 2027 * |
11x | P/E 2028 * | 11.7x |
|---|---|---|---|---|---|
| Enterprise Value | 3,720B 22.91B 20.11B 18.51B 17.25B 32.53B 2,178B 33.19B 223B 86.27B 1,069B 86.01B 84.15B | EV / Sales 2027 * |
1.65x | EV / Sales 2028 * | 1.64x |
| Free-Float |
98.88% | Yield 2027 * |
3.8% | Yield 2028 * | 3.91% |
Last Transcript: Astellas Pharma Inc.
| 1 day | +0.94% | ||
| 1 week | -0.35% | ||
| Current month | -1.63% | ||
| 1 month | -1.38% | ||
| 3 months | -17.73% | ||
| 6 months | +0.45% | ||
| Current year | +2.22% |
| 1 week | 2,105 |  | 2,204 |
| 1 month | 2,041 | | 2,204 |
| Current year | 2,041 | | 2,717 |
| 1 year | 1,365 | | 2,717 |
| 3 years | 1,243.5 | | 2,717 |
| 5 years | 1,243.5 | | 2,717 |
| 10 years | 1,243.5 | | 2,717 |
| Manager | Title | Age | Since |
|---|---|---|---|
Naoki Okamura
CEO | Chief Executive Officer | 63 | 10/02/2023 |
Kitamura Atsushi
DFI | Director of Finance/CFO | 54 | 01/11/2023 |
Tatjana Dragovic
CMP | Compliance Officer | - | 01/04/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Kenji Yasukawa
CHM | Chairman | 66 | 10/02/2023 |
Naoki Okamura
BRD | Director/Board Member | 63 | 01/06/2019 |
| Director/Board Member | 58 | 01/06/2023 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.94% | -0.35% | +53.75% | -0.23% | 23.38B | |
| -0.64% | +6.67% | +53.59% | +154.11% | 1,063B | |
| +0.00% | +5.39% | +62.89% | +53.44% | 611B | |
| -0.23% | +6.88% | +32.14% | +86.34% | 444B | |
| +1.78% | -0.96% | +26.12% | +20.22% | 324B | |
| +1.63% | +0.20% | +35.61% | +35.82% | 285B | |
| +0.90% | +0.08% | +28.11% | +42.42% | 283B | |
| -0.56% | +2.15% | -26.96% | -40.43% | 219B | |
| -0.22% | +2.82% | +24.37% | +62.75% | 195B | |
| -0.29% | +0.65% | +12.75% | +63.45% | 156B | |
| Average | +0.41% | +2.36% | +30.24% | +47.79% | 360.41B | |
| Weighted average by Cap. | +0.31% | +4.12% | +38.39% | +76.82% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 2,250B 13.85B 12.16B 11.2B 10.43B 19.68B 1,317B 20.08B 135B 52.18B 647B 52.02B 50.89B | 2,072B 12.76B 11.2B 10.31B 9.61B 18.12B 1,213B 18.48B 124B 48.04B 595B 47.89B 46.86B |
| Net income | 345B 2.12B 1.86B 1.71B 1.6B 3.01B 202B 3.07B 20.62B 7.99B 99.01B 7.97B 7.79B | 325B 2B 1.76B 1.62B 1.51B 2.84B 190B 2.9B 19.44B 7.53B 93.31B 7.51B 7.35B |
| Net Debt | -76.78B -473M -415M -382M -356M -671M -44.95B -685M -4.6B -1.78B -22.06B -1.78B -1.74B | -391B -2.41B -2.12B -1.95B -1.81B -3.42B -229B -3.49B -23.42B -9.07B -112B -9.04B -8.85B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/07/26 | ¥2,139.50 | +0.94% | 6,188,700 |
| 01/07/26 | ¥2,119.50 | -2.55% | 5,055,800 |
| 30/06/26 | ¥2,175.00 | +0.18% | 9,968,900 |
| 29/06/26 | ¥2,171.00 | +1.21% | 10,716,900 |
| 26/06/26 | ¥2,145.00 | -0.09% | 6,216,800 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4503 Stock
Select your edition
All financial news and data tailored to specific country editions
